• First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL

    The combination was associated with deep and durable responses in previously untreated high-risk CLL, SLL, and del(17p) and/or TP53 mutations.

  • Clinically meaningful outcomes for mosunetuzumab across FL subgroups

    High-risk participants with heavily pre-treated relapsed or refractory follicular lymphoma benefitted in clinical remission and survival outcomes.

  • AUGMENT-101: revumenib trial in KMT2Ar leukaemia stopped early for efficacy

    In a heavily pretreated population of participants with KMT2A rearranged acute leukaemia, revumenib displayed encouraging anti-tumour activity.

  • ESLIM-01: Sovleplenib delivers durable responses and QoL improvements in primary ITP

    Sovleplenib was associated with early and durable platelet responses in participants with primary immune thrombocytopenia.

  • Traffic noise could contribute to cardiovascular diseases

    Harmful environmental influences, such as air and noise pollution or light pollution at night, can also contribute to susceptibility to disease.

  • RUBY: Promising data for first AsCas12a gene-editing therapy in sickle cell disease

    Renizgamglogene autogedtemcel (reni-cel) established a swift and durable normalisation in haemoglobin and improvements in haemolysis markers.

  • Excellent phase 3 results for asciminib in CML

    Asciminib was superior to all other tested first-line tyrosine kinase inhibitors (TKIs) in participants with chronic myeloid leukaemia (CML).

  • EPCORE CLL-1: promising data for epcoritamab in high-risk Richter’s transformation

    Epcoritamab delivered encouraging efficacy data and a favourable safety profile in participants with high-risk Richter’s transformation (RT).

  • ENERGIZE: mitapivat meets primary efficacy endpoint in thalassaemia

    Mitapivat improved Hb levels and fatigue in participants with non-transfusion-dependent alpha or beta thalassaemia (NTDT) in a phase 3 study.

  • Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for MF?

    Treatment with pelabresib plus ruxolitinib was associated with improvements in all 4 hallmarks of myelofibrosis, the phase 3 MANIFEST-2 trial showed.

  • Navitoclax plus ruxolitinib leads to spleen volume reductions in MF in TRANSFORM-1 trial

    JAK inhibitor-naïve participants with myelofibrosis benefitted from a regimen of navitoclax plus ruxolitinib compared with ruxolitinib and a placebo.

  • Beans: powerful supporters in colorectal cancer aftercare

    The intestinal microbiome is essential in many body processes. Could prebiotic food intake benefit intestinal flora in intestinal polyps or colorectal carcinoma?

  • Promising results for novel CAR T-cell therapy in MM in phase 1 trial

    Anitocabtagene autoleucel (anito-cel) yielded excellent efficacy results in heavily pre-treated participants with relapsed or refractory multiple myeloma.

  • Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial

    Isatuximab with bortezomib, lenalidomide + dexamethasone yielded better outcomes than VRd alone for first-line treatment of transplant-ineligible cases.

  • FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML

    Treatment led to high measurable residual disease-negativity rates in European LeukaemiaNet subgroups for newly-diagnosed acute myeloid leukaemia.

  • Can golcadomide plus R-CHOP become the first-line standard of care in DLBCL?

    The combination delivered a high rate of durable complete metabolic responses regardless of cell of origin in aggressive B-cell lymphoma patients.

  • ECHO: Can we expect a novel standard of care in newly diagnosed MCL?

    Acalabrutinib added to bendamustine and rituximab decreased disease progression or death risks compared with BR and a placebo for mantle cell lymphoma.

  • AI can diagnose CNS tumours during surgery

    An AI algorithm called "Sturgeon" can classify CNS tumours fast and accurately during surgery. This enables resection strategies adapted to tumour types.

  • DREAMM 8: belantamab mafodotin offers hope for patients with RR MM

    Belantamab mafodotin plus pomalidomide and dexamethasone PVd for progression-free survival in participants with relapsed or refractory multiple myeloma.

  • High survival rates following atezolizumab consolidation therapy in DLBCL

    High-risk diffuse large B-cell lymphoma patients with a complete metabolic response (CMR) after R-CHOP benefitted from atezolizumab consolidation therapy.

  • 4 |
  • 5 |
  • 6 |
  • 7 |
  • 8 |
  • 9 |
  • 10 |
  • 11 |
  • 12 |
  • 13 |
  • 14 |